Cargando…

Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin

Apramycin represents a subclass of aminoglycoside antibiotics that has been shown to evade almost all mechanisms of clinically relevant aminoglycoside resistance. Model‐informed drug development may facilitate its transition from preclinical to clinical phase. This study explored the potential of ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sou, Tomás, Hansen, Jon, Liepinsh, Edgars, Backlund, Maria, Ercan, Onur, Grinberga, Solveiga, Cao, Sha, Giachou, Paraskevi, Petersson, Anna, Tomczak, Magdalena, Urbas, Malgorzata, Zabicka, Dorota, Vingsbo Lundberg, Carina, Hughes, Diarmaid, Hobbie, Sven N., Friberg, Lena E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048880/ https://www.ncbi.nlm.nih.gov/pubmed/33150591 http://dx.doi.org/10.1002/cpt.2104

Ejemplares similares

Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis
por: Becker, Katja, et al.
Publicado: (2021)

In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii
por: Juhas, Mario, et al.
Publicado: (2019)

Excretion of the Polymyxin Derivative NAB739 in Murine Urine
por: Vaara, Martti, et al.
Publicado: (2020)

Knockout of Tmlhe in mice is not associated with autism spectrum disorder phenotypes or motor dysfunction despite low carnitine levels
por: Liepinsh, Edgars, et al.
Publicado: (2023)

Synthesis, Antibacterial and Antiribosomal Activity of the 3C-Aminoalkyl Modification in the Ribofuranosyl Ring of Apralogs (5-O-Ribofuranosyl Apramycins)
por: Lubriks, Dmitrijs, et al.
Publicado: (2022)

Characterization of prickle isoform-specific pk (pk1) and pk (sple1) mutations in Drosophila melanogaster
por: Lilienthal, Anthony J, et al.
Publicado: (2022)

Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
por: Zhao, Chenyan, et al.
Publicado: (2022)

Metformin decreases bacterial trimethylamine production and trimethylamine N-oxide levels in db/db mice
por: Kuka, Janis, et al.
Publicado: (2020)

Inhibition of Fatty Acid Metabolism Increases EPA and DHA Levels and Protects against Myocardial Ischaemia-Reperfusion Injury in Zucker Rats
por: Kuka, Janis, et al.
Publicado: (2021)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study
por: Haliduola, Halimu N., et al.
Publicado: (2022)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

Decreases in Circulating Concentrations of Long-Chain Acylcarnitines and Free Fatty Acids During the Glucose Tolerance Test Represent Tissue-Specific Insulin Sensitivity
por: Makarova, Elina, et al.
Publicado: (2019)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Low‐intensity exercise stimulates bioenergetics and increases fat oxidation in mitochondria of blood mononuclear cells from sedentary adults
por: Liepinsh, Edgars, et al.
Publicado: (2020)

Prediction of Clinical Irrelevance of PK Differences in Atorvastatin Using PK/PD Models Derived From Literature-Based Meta-Analyses
por: Vargo, R, et al.
Publicado: (2014)

1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019)

MF-SuP-pK(a): Multi-fidelity modeling with subgraph pooling mechanism for pK(a) prediction
por: Wu, Jialu, et al.
Publicado: (2023)

Complete Genome Sequence of the Pokeweed Mosaic Virus (PkMV)-New Jersey Isolate and Its Comparison to PkMV-MD and PkMV-PA
por: Di, Rong
Publicado: (2016)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

PK-DB: pharmacokinetics database for individualized and stratified computational modeling
por: Grzegorzewski, Jan, et al.
Publicado: (2020)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Importance of Co‐operative Hydrogen Bonding in the Apramycin‐Ribosomal Decoding A‐Site Interaction
por: Pirrone, Michael G., et al.
Publicado: (2022)

1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
por: Maas, Brian, et al.
Publicado: (2018)

Benchmarking pK(a )prediction
por: Davies, Matthew N, et al.
Publicado: (2006)

In silico pK(a) prediction
por: Körner, Robert, et al.
Publicado: (2012)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Impact of saturable distribution in compartmental PK models: dynamics and practical use
por: Peletier, Lambertus A., et al.
Publicado: (2017)

Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?
por: Duong, Alexandre, et al.
Publicado: (2021)

PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor
por: Schindler, E, et al.
Publicado: (2016)

PK-sensitive PrP(Sc) Is Infectious and Shares Basic Structural Features with PK-resistant PrP(Sc)
por: Sajnani, Gustavo, et al.
Publicado: (2012)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Depletion of pyruvate kinase (PK) activity causes glycolytic intermediate imbalances and reveals a PK-TXNIP regulatory axis
por: Nieborak, Anna, et al.
Publicado: (2023)

Ionization Constants pK(a) of Cardiolipin
por: Olofsson, Gerd, et al.
Publicado: (2013)

DNA-PK as an Emerging Therapeutic Target in Cancer
por: Mohiuddin, Ismail S., et al.
Publicado: (2019)

Machine learning meets pK (a)
por: Baltruschat, Marcel, et al.
Publicado: (2020)

Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
por: Zhang, Wantong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4r9vhetlkie9o2nagtigsk2sai